CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
- S. Perea, O. Reyes, B. Acevedo
- BiologyMolecular and Cellular Biochemistry
- 25 June 2008
These results provide an early proof-of-principle of clinical benefit by using an anti-CK2 approach in cancer and are the first clinical trial where an investigational drug has been used to target the CK2 phosphorylation domain.
Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1.
- S. Perea, P. Massimi, L. Banks
- BiologyInternational Journal of Molecular Medicine
- 1 June 2000
The data indicate that HPV-16 E7 inhibits the IRF-1 and NFkappaB function and this could lead to the impairment of the IFN response in HPV-infected cells and the findings suggest that different events of theIFN inducible signal cascade seem to be target for HPV- 16 E7.
Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.
- Y. Perera, Neylen Del Toro, Larisa Gorovaya, J. Fernández-de-Cossio, H. Farina, S. Perea
- BiologyMolecular and clinical oncology
- 1 November 2014
Findings provide a rationale for combining the anti-CK2 CIGB-300 peptide with currently available anticancer agents in the clinical setting and indicate platins and taxanes as compounds with major perspectives.
Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
Findings provide important clues by which the CIGB-300 peptide exerts its proapoptotic effect on tumor cells and highlights the suitability of the B23/CK2 pathway for cancer-targeted therapy.
Detection and typing of human papillomavirus DNA in benign and malignant tumours of laryngeal epithelium.
- R. Garcia-Milian, H. Hernández, S. Perea
- MedicineActa Oto-Laryngologica
HPV 16 was the type most frequently found in laryngeal carcinoma samples and this results support an etiologic role for this type of HPV in the pathogenesis of larynx carcinoma.
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
- L. R. Cruz, I. Baladrón, S. Perea
- 15 September 2020
This first report describing signs of clinical benefit of an anti-CK2 approach in Covid-19 is described, revealing that consecutive-5 day regimen of intravenous CIGB-325 at 2.5 mg/kg quickly improved the chest-CT outcomes over standard-of-care.
CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome
Evidence is provided for the first evidence for a direct impairment of CK2 enzymatic activity by CIGB-300, which may help to explain the different anti-neoplastic effects exerted by this anticancer peptide in preclinical cancer models.
Obtaining Biologically Active IL-15 in Escherichia coli ; Obtención de IL-15 Biológicamente Activa en Escherichia coli
- Alicia Santos, Y. Morera, S. Perea
The cDNA of human IL-15 was cloned into a prokaryotic vector under control of the tryptophan promoter for its expression in Escherichia coli, making this cytokine easily available for in vitro and therapeutic studies.
Differential expression of the p27Kip1 mRNA in IFN-sensitive and resistant cell lines.
- A. Moro, A. Calixto, E. Suárez, M. Araña, S. Perea
- BiologyBiochemical and Biophysical Research…
The results suggest that p27Kip1 could be a key mediator of the IFN alpha 2b-induced growth arrest and that HPV 16 E7 might affect p27 kip1 inducibility, originating IFNalpha 2B-resistant cells.
CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
- S. Perea, I. Baladrón, C. Valenzuela, Y. Perera
- Biology, ChemistrySeminars in Oncology
The clinical data demonstrate the safety, tolerability, and clinical effects of intratumoral injections of CIGB-300 and provide the foundation for future phase 3 clinical trials in locally advanced cervical cancer in combination with standard chemoradiotherapy.